FDA approved eflornithine for high-risk neuroblastoma in December 2023
The agency cleared the drug, marketed as IWILFIN by USWM, LLC, for patients who had responded at least partially to prior multiagent, multimodality therapy.
The Food and Drug Administration approved eflornithine, sold under the brand name IWILFIN by USWM, LLC, on December 13, 2023.1
The approval covers both adult and pediatric patients with high-risk neuroblastoma. Specifically, the drug is indicated to lower the chance of disease relapse in patients who have already shown at least a partial response to prior treatment involving multiple agents and multiple treatment modalities.1
This story is based on an FDA record of the approval. The document does not provide additional details on dosing, trial data, or company statements regarding the approval.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.